Addressing International Antimicrobial Resistance
March 30th 2022The Center for Global Development is launching a new working group, which aims to address antimicrobial resistance by exploring how to improve incentives for pharmaceutical companies to develop new antimicrobials for low-income and middle-income countries (LMICs).
Pfizer-BioNTech and Moderna mRNA Vaccines Elicit Different Antibody Responses
March 30th 2022The Pfizer-BioNTech and Moderna mRNA vaccines were found to produce different antibody and killer T-cell responses, suggesting a “mix and match” booster approach may provide the best protection against COVID-19.
Sotrovimab Distribution Paused in Areas Where BA.2 Is Dominant COVID-19 Variant
March 28th 2022The Assistant Secretary for Preparedness and Response (ASPR) announced a pause in sotrovimab distribution in regions where BA.2 is the dominant COVID-19 variant, citing evidence that the monoclonal antibody therapy would not effectively neutralize the BA.2 Omicron variant.
Label Update for Cabotegravir and Rilpivirine Long-Acting HIV Treatment
March 24th 2022With FDA Approval, the oral lead-in for the cabotegravir and rilpivirine long-acting HIV treatment (Cabenuva) is now optional. Clinical trial data showed similar safety and efficacy profiles for initiating the therapy with or without the oral lead-in.
“Ramp Up the Resources”: Increased Effort and Funding Needed to End HIV
March 23rd 2022Congress’s spending bill allocated drastically less funding for HIV testing, prevention, and treatment than previously promised. Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, explains why it is so vital to continue the fight against HIV.